Shuo Ma

16PUBLICATIONS
88CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursMolecular targetsPredictive and prognostic markersChemotherapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (16)

|Jul 28, 2026
Lisocabtagene maraleucel combined with ibrutinib in R/R CLL or SLL: primary results from TRANSCEND CLL 004.

|Jan 16, 2026
Pirtobrutinib, a highly selective, noncovalent (reversible) BTKi in R/R marginal zone lymphoma: phase 1/2 BRUIN study.

Krish Patel, Julie M Vose, Sunita D Nasta

|Nov 07, 2025
Outcomes for CART as 2L vs 3L vs 4L or beyond in aggressive B-cell lymphoma: real-world evidence from the ABC Consortium.

John S Wang, Brandon L Ellsworth, Megan Melody

|Aug 22, 2025
Pirtobrutinib, a highly selective, noncovalent (reversible) BTKi in R/R follicular lymphoma: phase 1/2 BRUIN study.

Nirav N Shah, Pier Luigi Zinzani, Michael Wang

|Jul 24, 2025
Nivolumab in combination with R-CHOP for treatment-naïve diffuse large B-cell lymphoma: an evaluation of safety and efficacy.

Oluwatobi Odetola, Shuo Ma, Jane Winter

|Mar 27, 2025
Double hit & double expressor lymphomas: a multicenter analysis of survival outcomes with CD19-directed CAR T-cell therapy.

Reem Karmali, Geoffrey Shouse, Pallawi Torka

Pageof 3

Frequent Collaborators

11 joint publications

Reem Karmali

10 joint publications

Leo I Gordon

9 joint publications

Nirav N Shah

7 joint publications

Jonathon B Cohen